JP2019517790A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517790A5
JP2019517790A5 JP2018559282A JP2018559282A JP2019517790A5 JP 2019517790 A5 JP2019517790 A5 JP 2019517790A5 JP 2018559282 A JP2018559282 A JP 2018559282A JP 2018559282 A JP2018559282 A JP 2018559282A JP 2019517790 A5 JP2019517790 A5 JP 2019517790A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
chain domain
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517790A (ja
Filing date
Publication date
Priority claimed from GBGB1608052.5A external-priority patent/GB201608052D0/en
Application filed filed Critical
Publication of JP2019517790A publication Critical patent/JP2019517790A/ja
Publication of JP2019517790A5 publication Critical patent/JP2019517790A5/ja
Pending legal-status Critical Current

Links

JP2018559282A 2016-05-09 2017-05-09 TGFβRIIのフレームシフト変異体を認識するT細胞受容体 Pending JP2019517790A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
GB1608052.5 2016-05-09
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII

Publications (2)

Publication Number Publication Date
JP2019517790A JP2019517790A (ja) 2019-06-27
JP2019517790A5 true JP2019517790A5 (enExample) 2020-06-18

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559282A Pending JP2019517790A (ja) 2016-05-09 2017-05-09 TGFβRIIのフレームシフト変異体を認識するT細胞受容体

Country Status (13)

Country Link
US (1) US20190336529A1 (enExample)
EP (1) EP3455249B1 (enExample)
JP (1) JP2019517790A (enExample)
KR (1) KR20190016507A (enExample)
CN (1) CN109328196B (enExample)
AU (1) AU2017261684A1 (enExample)
CA (1) CA3024555A1 (enExample)
EA (1) EA201892217A1 (enExample)
GB (1) GB201608052D0 (enExample)
IL (1) IL262873A (enExample)
MX (1) MX2018013581A (enExample)
SG (1) SG11201809716VA (enExample)
WO (1) WO2017194555A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) * 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
KR20200063215A (ko) * 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
US12275773B2 (en) 2018-09-21 2025-04-15 Xlifesc, Ltd. High affinity cell receptor for recognizing AFP antigen
US20220193137A1 (en) * 2019-04-04 2022-06-23 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
AU2024312524A1 (en) * 2023-06-20 2026-01-22 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
TW202506712A (zh) * 2023-06-21 2025-02-16 大陸商北京可瑞生物科技有限公司 經修飾的tcr恒定區及其在tcr融合蛋白中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
FR2779432A1 (fr) * 1998-06-08 1999-12-03 Transgene Sa Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations
KR20120063475A (ko) * 2009-07-29 2012-06-15 글락소 그룹 리미티드 항-tgf-베타 수용체 타입 ⅱ 단일 도메인 항체
PH12013502489B1 (en) * 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Similar Documents

Publication Publication Date Title
JP7346294B2 (ja) 対合が改善されたt細胞受容体t細胞
BR112018070741A2 (pt) receptor de células t (tcr), tcr que se liga a um complexo hla-a*02, molécula de fusão a anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou projetada, composição farmacêutica, método de tratamento de um indivíduo humano em necessidade deste, formulação injetável para administração a um indivíduo humano, e método de produção de um tcr
JP2017537627A5 (enExample)
JP2017501130A5 (enExample)
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
JP2017501129A5 (enExample)
JP2018509163A5 (enExample)
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
JP2019500894A5 (enExample)
IL259120A (en) Her2-targeted antigen chimeric receptors2
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
BR112019027291A2 (pt) receptores de células t, molécula de fusão anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, composição farmacêutica, método de tratar um sujeito humano que tem câncer, formulação injetável para administrar a um sujeito humano e método de produzir um tcr
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
RU2016124179A (ru) СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека
JP2016505635A5 (enExample)
RU2022103870A (ru) Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента
NZ739448A (en) Transgene genetic tags and methods of use
JP2014500724A5 (enExample)
EA201892217A1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
JP2017006120A5 (enExample)
PH12014500720A1 (en) Topk peptides and vaccines including the same
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
RU2020100072A (ru) Иммуногенные композиции, содержащие cea, muc1 и tert
JP2020526202A5 (enExample)
JP2025063330A (ja) 対合が改善されたt細胞受容体t細胞